YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion - Wikidata - awgldk - TriplyDB

YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion

YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion

http://www.wikidata.org/entity/Q28477993

about

The RNA helicase A in malignant transformation A small molecule inhibitor of ETV1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines Structures of the Ets Protein DNA-binding Domains of Transcription Factors Etv1, Etv4, Etv5, and Fev: DETERMINANTS OF DNA BINDING AND REDOX REGULATION BY DISULFIDE BOND FORMATION.Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1.The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.Metadherin mediates lipopolysaccharide-induced migration and invasion of breast cancer cells.A small molecule that binds and inhibits the ETV1 transcription factor oncoprotein The ETS family of oncogenic transcription factors in solid tumours.Targeted therapies for advanced Ewing sarcoma family of tumors.Oncogenic activation of ERG: A predominant mechanism in prostate cancer.ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors.YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model.Regulation of CXCR4-mediated invasion by DARPP-32 in gastric cancer cells Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer Androgen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells.Recent advances in the structural molecular biology of Ets transcription factors: interactions, interfaces and inhibition.Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer.Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.The oncogene ERG: a key factor in prostate cancer.The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis Drug discovery in advanced prostate cancer: translating biology into therapy.ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents.Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma.Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-β→MMP-9 signals.Erg and AP-1 as determinants of glucocorticoid response in acute lymphoblastic leukemia.Potential for targeted therapy in prostate cancers with ERG abnormalities.Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer.Modeling the Mechanism of GR/c-Jun/Erg Crosstalk in Apoptosis of Acute Lymphoblastic Leukemia.Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer.Ethnicity and ERG frequency in prostate cancer.EWS-FLI1 and RNA helicase A interaction inhibitor YK-4-279 inhibits growth of neuroblastoma.Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer.

P2860

Q26765181-A975E3C8-2E82-4EC7-B13F-2CEC6ADB1E1F Q27322372-5338E587-F82C-4B53-A5A7-156444CD2B0F Q28771722-E6E24D0C-A4AE-445B-B3EB-39E3A4C50FD4 Q30373611-2BA050D6-8232-4E22-B8F8-13A44449F3F4 Q30427325-7487F2B0-39DE-415D-B2D5-0D9852B4E43C Q33702987-98BBC52A-6BAA-4E35-B2D7-1C15636A4A6E Q34110914-E86F7E25-A35A-43E1-B87A-C16B9B8E238C Q34132931-9D105C97-CE76-49D8-938D-6D93F8270AB7 Q34555986-253A260F-5599-455A-AD2B-BE5279D4C826 Q35589492-EE73825A-E79B-4F54-9E70-845CDBA81EC9 Q35685920-9879A640-8184-4220-908B-F03E8EBB52FB Q35996105-9E0DF12E-1B71-4F4C-AD49-97A01EE698E0 Q36545848-92264801-A814-4E95-9451-75D1D3E7FCBA Q36553388-0D3B8FD4-9B88-4CA6-95F4-FD6BAF0C40D2 Q37272420-4405470E-D25A-4E09-81DD-8D175F10B8C1 Q37727814-9AC5AD75-8A53-49AF-B468-24E3B7341829 Q38180770-D957F0B7-3D0C-4690-BE20-8F6BA620CB13 Q38243878-F7BC9D0B-6556-464D-A92D-6B6414FC98A7 Q38330339-020C27EA-BD47-42F8-8A38-227CF44D2EDF Q38405404-60C3E034-88C3-41C4-852F-149E4AA51A79 Q38444138-810A62FC-19D5-417D-BD72-D73BA95C6D25 Q38700629-96083C6C-EBFE-4CDA-A870-DDB2C8FC47B6 Q38839110-7C3883F4-6BAB-43EE-8D4F-FD433579C043 Q38883101-0F7462DB-1781-4C9E-A910-AA326461FD81 Q39113281-5CBF1D89-4AF4-43F3-9138-4B6272D4271D Q39164084-7D13EE2B-8344-4F95-8ED9-6EAFE940B284 Q39174448-32953B6D-AA20-453E-A027-607A6BF67D21 Q39301443-922A9916-8E75-4C2E-A46D-118A3E2CB0DA Q39501622-71F4898F-3192-42FB-9A4D-C4FF9FBCEC72 Q40028950-74A3325E-969E-4CC9-BC4A-19D9A5ED2B0E Q41447345-2F5185B0-F7B1-4C0A-A34E-A5A54AB5C8AD Q42335698-3EED3A3B-4F48-429A-A69B-4983D64671B6 Q46504038-E45D58B2-0B83-4DA4-A121-61A1C315BBAD Q47140740-8BF0E376-6E40-4036-BC1F-3EB9FE4F38DD Q55343985-6B174A0B-3805-4BE9-BE36-EF46299DE06A

P2860

YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion

http://www.wikidata.org/entity/Q28477993

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion

@ast

YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion

@en

YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion

@nl

type

label

YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion

@ast

YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion

@en

YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion

@nl

prefLabel

YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion

@ast

YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion

@en

YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion

@nl

P1433

Q28477993-16308ED6-2190-4CE7-9F69-6FBFFC787D86

P1476

Q28477993-7FE48F0D-530F-4395-9BBA-2E5AFD67FDD6

P2093

Q28477993-25DA9CDA-9D71-4372-B488-DCD269DE2444

Q28477993-2A15ED73-EB08-4621-83F5-F5419DA12972

Q28477993-2AE4E6D0-8F62-4D60-90D8-C260A90EC0CC

Q28477993-927258F3-7A6B-4113-A208-2F93E9F66DA8

Q28477993-DD3555B7-E3FE-4466-8DE5-9957DADEECF8

Q28477993-F0E83415-1ED4-4C19-9E27-95A01B779667

P2860

Q28477993-0284B242-23B1-4089-908E-AD968074FF43

Q28477993-046D8845-01D9-4C2B-BAD2-03A0021F4EDF

Q28477993-05CA8ABD-B681-4238-86E5-DA4E4AE98969

Q28477993-1EF57195-7D8A-492C-AFF5-AAE392D5DDB2

Q28477993-3AEB2D3B-C8BE-41A8-A062-D5F60B79C3FB

Q28477993-522BC386-EF76-4E75-AB4D-5BAB4A8C6977

Q28477993-5BE61330-30F9-452B-B0B3-E5D96B171834

Q28477993-647BA37D-3871-472F-B4E6-3823F03BBB96

Q28477993-65AF416E-72B2-4FB9-9C69-273DF4282BF1

Q28477993-6631485E-50E2-4C3A-B82E-7B61D655AB43

P304

Q28477993-67D2D6C5-1D54-4711-9075-797401F635FF

P31

Q28477993-E18E82BB-2094-4408-9B36-3CB4B4BD1DCF

P356

Q28477993-B36DE010-D393-47B5-A201-BE7101CE7F7B

P407

Q28477993-32F04AED-C317-4D2C-AA0B-68A4A6FDB44F

P433

Q28477993-B4F1B53E-87B7-4247-B9BC-5151DF99D935

P478

Q28477993-A496042F-91CB-475C-987D-BE47FFAF227A

P577

Q28477993-D36FD9E3-2834-46CB-BD26-54DA8E95231D

P5875

Q28477993-28265D92-5F9D-4383-A390-53A2B507BEC8

P698

Q28477993-AB35E04B-B3A9-4329-A824-E99C62004CBA

P932

Q28477993-58622F07-A2EF-411B-AAC0-C0EB95CE932B

P356

JOURNAL.PONE.0019343

P1433

P1476

YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion

@en

P2093

Aykut Üren

http://www.w3.org/2001/XMLSchema#string

Elspeth M Beauchamp

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Toretsky

http://www.w3.org/2001/XMLSchema#string

Milton L Brown

http://www.w3.org/2001/XMLSchema#string

Said Rahim

http://www.w3.org/2001/XMLSchema#string

Yali Kong

http://www.w3.org/2001/XMLSchema#string

P2860

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Role of the TMPRSS2-ERG gene fusion in prostate cancer

Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A.

Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo

Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues.

Matrix metalloproteinases: roles in cancer and metastasis.

ETS transcription factors and their emerging roles in human cancer.

The Ets transcription factors of the PEA3 group: transcriptional regulators in metastasis.

GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein.

P304

e19343

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0019343

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51114473

http://www.w3.org/2001/XMLSchema#string

P698

21559405

http://www.w3.org/2001/XMLSchema#string

P932

3084826

http://www.w3.org/2001/XMLSchema#string